Skip to Content

Nanosonics Ltd NAN

Morningstar Rating
A$2.87 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Shares in Nanosonics Screen As Undervalued

Nanosonics’ Trophon solution for high-level disinfection of ultrasound probes has garnered substantial market share, evidenced by penetration of over 75% in Australia and New Zealand and 40% in North America. We expect elevated growth over the next three years as Trophon continues to gain share in North America and launch in Japan, but high market penetration may be more challenging to achieve in developing economies, which may not be able to prioritize nuanced disinfection standards. Moreover, the device patent expires in 2025, leading to slower volume growth in the medium term.

Price vs Fair Value

NAN is trading at a 344% premium.
Price
A$2.87
Fair Value
A$3.00
Uncertainty
High
1-Star Price
A$7.50
5-Star Price
A$5.70
Economic Moat
Btzxw
Capital Allocation
Gdbtvhry

Bulls Say, Bears Say

Bulls

Nanosonics is the market leader in automated HLD of ultrasound probes with significant further market penetration potential in most regions.

Bears

Nanosonics is a single-product company with a pipeline product that is largely unproven.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NAN is a good fit for your portfolio.

Trading Information

Previous Close Price
A$2.87
Day Range
A$2.782.88
52-Week Range
A$2.595.00
Bid/Ask
A$2.86 / A$2.88
Market Cap
A$869.60 Mil
Volume/Avg
954,412 / 1.1 Mil

Key Statistics

Price/Earnings (Normalized)
55.55
Price/Sales
5.31
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Nanosonics is a single-product firm and its Trophon device provides high-level disinfection of ultrasound probes used in semicritical procedures. The patented technology uses low-temperature sonically activated hydrogen peroxide mist suitable for probes sensitive to damage. Automated HLD is increasingly being used as the standard of care globally as it is superior in preventing cross-infection of patients. Nanosonics’ revenue is made up of capital sales of Trophon units, ongoing consumables sales, and service revenue. By June 2022, there were 29,850 Trophon units installed globally. Market penetration rates range from over 75% in Australia and New Zealand, about 44% in the U.S. to low-single-digit penetration in Europe, Middle East, and Africa, and elsewhere in the Asia-Pacific region.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Small Growth
Total Number of Employees
400

Competitors

Valuation

Metric
NAN
FPH
RMD
Price/Earnings (Normalized)
55.5582.0125.69
Price/Book Value
4.959.765.86
Price/Sales
5.319.816.00
Price/Cash Flow
36.5040.1421.57
Price/Earnings
NAN
FPH
RMD

Financial Strength

Metric
NAN
FPH
RMD
Quick Ratio
5.260.881.32
Current Ratio
6.561.833.04
Interest Coverage
12.4613.7722.63
Quick Ratio
NAN
FPH
RMD

Profitability

Metric
NAN
FPH
RMD
Return on Assets (Normalized)
9.04%11.54%15.75%
Return on Equity (Normalized)
11.94%15.07%24.94%
Return on Invested Capital (Normalized)
9.96%13.94%19.33%
Return on Assets
NAN
FPH
RMD
See how this stock stacks up to its competitors with Morningstar Investor

Medical Instruments & Supplies Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Intuitive Surgical Inc
ISRG
HpkdmyksNhqg$154.7 Bil
Becton Dickinson & Co
BDX
GqtvlhmWnpcjtp$66.3 Bil
Alcon Inc
ALC
SyyrbxggDpkrqd$43.9 Bil
ResMed Inc
RMD
NtwtdxptzYlndywp$27.5 Bil
Coloplast A/S ADR
CLPBY
KpplrnkqgVbqf$27.0 Bil
West Pharmaceutical Services Inc
WST
GldfbbhgqlMnkb$23.8 Bil
Hologic Inc
HOLX
ZtxgtfhzLmtmq$17.3 Bil
The Cooper Companies Inc
COO
ZclqplxFfwktxd$17.2 Bil
Baxter International Inc
BAX
XmvbzwkrMbjtcbg$16.8 Bil
Teleflex Inc
TFX
WzpnmYxlsn$10.0 Bil

Sponsor Center